Onlyglim-MV2

CD Care
CD Care

Onlyglim-MV2

Metformin HCI (SR), Glimepiride & Voglibose Tablets

  • Postprandial Hyperglycemia is now recognized as a Significant Risk Factor for Macrovascular Disease, lndepdent of HbA1C
  • In Diabetics lnadequately Controlled on Dual Therapy
  •  Synergistic Action for Optimal HbA1c Reduction

 Glimepiride 2 mg + Metformin 500 mg (SR) + Voglibose 0.2 mg

  • The triple drug fixed dose combination significantly
  • HbA1c value
  • Fasting plasma glucose level
  •  Post prandial glucose level

NEXINA

Related Products